Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Other Intangible Assets (Tables)

v3.5.0.2
Note 4 - Other Intangible Assets (Tables)
9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]
           
As of September 30, 2016
   
As of December 31, 2015
 
   
Life
   
Carrying
   
Carrying
 
   
(Years)
   
Amount
   
Amount
 
Diagnostic assets:
 
 
 
 
 
 
 
 
 
 
 
 
Asuragen acquisition:
                       
Thyroid
    9     $ 8,519     $ 8,519  
Pancreas
    -       -       2,882  
Biobank
    -       -       1,575  
RedPath acquisition:
                       
Pancreas test
    7       16,141       16,141  
Barrett's test
    9       18,351       18,351  
Total
          $ 43,011     $ 47,468  
Diagnostic lab:
 
 
 
 
 
 
 
 
 
 
 
 
CLIA Lab
    2.3     $ 609     $ 609  
                         
Accumulated Amortization
          $ (6,400 )   $ (4,585 )
                         
Net Carrying Value
          $ 37,220     $ 43,492  
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
2016
   
2017
   
2018
   
2019
   
2020
 
$ 3,771     $ 4,272     $ 5,292     $ 5,292     $ 5,292